vs-6766, a unique inhibitor of the raf/mek signaling pathway for patients with kras mutant tumors
Published 3 years ago • 142 plays • Length 2:21Download video MP4
Download video MP3
Similar videos
-
2:21
phase 2 registration-directed trial of vs-6766 and defactinib
-
6:29
ras raf mek erk signaling and the mtor pathway | interactions and regulation
-
6:46
dr. camidge discusses launch of phase 2 trial evaluating raf/mek inhibitor in nsclc
-
4:07
understanding resistance to combined braf and mek inhibiton in melanoma and the significance of cdk4
-
6:10
ras raf mek erk pathway - introduction
-
2:03
sos1::kras inhibitor (bi 1701963): mechanism of action
-
1:35
#esmo21 highlights on a phase i of dual raf/mek inhibitor fak inhibitor in ovarian cancer (frame)
-
10:03
activatory mutations in kras part 2
-
24:33
molecular markers beyond kras for anti-egfr targeted agents — what is new?
-
3:41
combining jak, pim kinase and cdk4/6 inhibition in mpns
-
1:18
scrna-seq of the immune microenvironment reveals immunotherapy response biomarkers in high-risk smm
-
20:47
the ras / raf / mek / erk pathway part 1
-
4:57
selpercatinib benefit for advanced, kinase inhibitor-naïve, ret-mutant medullary thyroid cancer
-
2:31
predictive biomarkers in kras-altered nsclc treated with checkpoint inhibitors
-
8:28
fulvestrant in the era of cdk4/6 inhibitors for hr mbc
-
0:15
revolutionary blood & plasma kits: the secret to better research?
-
13:32
noacs should replace warfarin in all patients with atrial fibrillation - pro - j. camm
-
0:51
bio-rad qpcr supermixes: innovative reagents for superior performance
-
6:17
when to choose chemotherapy vs cdk4/6 inhibitors